Background: The development of novel therapeutic agents requires comprehensive understanding of pharmacokinetics, pharmacodynamics, and pharmacogenomics.

Methods: We conducted molecular docking, pharmacogenomics analysis, in vitro pharmacokinetics, and pharmacodynamics studies on Compound A.

Results: Compound A demonstrated strong binding affinity, favorable pharmacokinetics, and pharmacodynamics profiles. Pharmacogenomics analysis identified genetic variants associated with altered drug response.